Replies to post #220470 on Biotech Values

[DewDiligence]

Mavyret’s US new-patient share=51.7%—the highest-ever weekly figure—in the week ending 8/10/18, as reported by IMS. GILD’s US new-patient share was 47.4%, and MRK’s was 1.0%.

Mavyret’s US total-script share reached 46.4% in the week ending 8/10/18, also the highest-ever weekly figure, as reported by IMS. GILD’s US total-script share was 51.8%, and MRK’s was 1.8%.